Johnson & Johnson (JNJ)

$213.03 +3.31 (1.58%)
Market Cap 492.44B
Revenue (ttm) 88.82B
Net Income (ttm) 14.07B
EPS (ttm) N/A
PE Ratio 19.69
Forward PE 17.92
Profit Margin 15.84%
Debt to Equity Ratio 0.50
Volume 4,668,469
Avg Vol 8,448,722
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 98%
Beta 0.34
Analysts Strong Sell
Price Target $213.21

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
SmartMoneyTradez
SmartMoneyTradez Jan. 13 at 6:02 PM
$GFS 40 > 45 > 50 $JNJ bullish
0 · Reply
ROCKSTAR_X
ROCKSTAR_X Jan. 13 at 5:19 PM
$JNJ 215 eod. possible?
0 · Reply
JohnTrack
JohnTrack Jan. 13 at 4:42 PM
$JNJ new data at 2026 American College of Neuropsychopharmacology Annual Meeting https://www.rapidticker.com/news/jnj-johnson-johnson-elevates-leadership-in-5b48d7
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 13 at 4:06 PM
$JNJ Current Stock Price: $213.13 Contracts to trade: $210 JNJ Jan 16 2026 Call Entry: $3.60 Exit: $4.77 ROI: 32% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SparkyReturns
SparkyReturns Jan. 13 at 2:55 PM
$ICU Something's up.. us. Biggest sleeper in biotech right now. GL longs. $JNJ $AMGN $MRK $MCK
0 · Reply
ConradW_
ConradW_ Jan. 13 at 2:26 PM
$JNJ Dec +7% MoM revenue lines up clean with the actual dollars: $8.01M minus $7.51M equals +$0.50M. Clean math, clean signal, no hand-waving 🔥
0 · Reply
DragonAlgo
DragonAlgo Jan. 13 at 2:21 PM
🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-01-16 | Strike: $210.00 | Type: CALL Option Plan (premium): Entry: $2.05 Stop: $1.48 TP1: $2.67 TP2: $3.48 TP3: $4.92 🔗 https://dragonalgo.com
0 · Reply
DarioQ
DarioQ Jan. 13 at 2:02 PM
$JNJ defensive anchor, if it keeps grinding higher that’s risk-off comfort without killing upside
0 · Reply
Quantumup
Quantumup Jan. 13 at 1:57 PM
BTIG reiterated $LQDA Buy/$49 $UTHR $JNJ $MRK $INSM Here's what BTIG said: https://x.com/Quantumup1/status/2011073992057139619?s=20
0 · Reply
unton
unton Jan. 13 at 1:43 PM
$PFE $MRNA $AZN $JNJ $DCOY one single pill for all types of COVID.”
0 · Reply
Latest News on JNJ
Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

Jan 13, 2026, 8:00 AM EST - 5 hours ago

Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors

Jan 13, 2026, 2:40 AM EST - 10 hours ago

Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors

DHR GOOG LIN MSFT ORCL

Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top court

Jan 12, 2026, 6:32 PM EST - 18 hours ago

Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top court

Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 2:06 PM EST - 22 hours ago

Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

Jan 11, 2026, 7:40 AM EST - 2 days ago

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

AMGN CVX HD KO MRK NKE PG

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Jan 10, 2026, 10:00 AM EST - 3 days ago

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

Jan 10, 2026, 9:52 AM EST - 3 days ago

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

AMGN CRM DIS HD HON KO MRK

Cramer's Mad Dash: Johnson & Johnson

Jan 9, 2026, 9:59 AM EST - 4 days ago

Cramer's Mad Dash: Johnson & Johnson

Johnson & Johnson Strikes Deal With White House to Lower Drug Prices

Jan 9, 2026, 5:10 AM EST - 4 days ago

Johnson & Johnson Strikes Deal With White House to Lower Drug Prices

Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices

Jan 8, 2026, 9:33 PM EST - 4 days ago

Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices

Johnson & Johnson reaches deal with US government to lower drug prices

Jan 8, 2026, 8:43 PM EST - 4 days ago

Johnson & Johnson reaches deal with US government to lower drug prices

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

Jan 8, 2026, 8:24 PM EST - 4 days ago

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration

Jan 7, 2026, 8:00 AM EST - 6 days ago

Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

Jan 6, 2026, 8:03 AM EST - 7 days ago

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma

Jan 6, 2026, 6:52 AM EST - 7 days ago

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

Jan 2, 2026, 5:06 PM EST - 10 days ago

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

AMGN CVX HD KO MRK NKE PG

Dow Jones 2025 Scorecard: Caterpillar, Nvidia Help Index Hit All-Time Highs – Top 5 Winners & Losers

Jan 2, 2026, 4:17 PM EST - 10 days ago

Dow Jones 2025 Scorecard: Caterpillar, Nvidia Help Index Hit All-Time Highs – Top 5 Winners & Losers

CAT NVDA GS IBM

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026

Jan 2, 2026, 8:00 AM EST - 11 days ago

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026

Best Dividend Aristocrats For January 2026

Dec 31, 2025, 8:47 AM EST - 13 days ago

Best Dividend Aristocrats For January 2026

ABBV ABT ADM ADP AFL ALB AMCR

The Big 3: JNJ, SNDK, TWLO

Dec 30, 2025, 1:31 PM EST - 13 days ago

The Big 3: JNJ, SNDK, TWLO

TWLO SNDK

Jim Cramer Says ‘The Year of Magical Investing' Is Over—Here's What To Do Now

Dec 30, 2025, 9:55 AM EST - 14 days ago

Jim Cramer Says ‘The Year of Magical Investing' Is Over—Here's What To Do Now

PG

More Upside For JNJ Stock In 2026?

Dec 30, 2025, 5:05 AM EST - 14 days ago

More Upside For JNJ Stock In 2026?

Dogs of the Dow Had a Strong Year as Dividends Paid Off

Dec 29, 2025, 1:56 PM EST - 14 days ago

Dogs of the Dow Had a Strong Year as Dividends Paid Off

HD IBM NKE UNH

Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

Dec 29, 2025, 8:00 AM EST - 15 days ago

Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

Best Dividend Kings: December 2025

Dec 28, 2025, 6:44 AM EST - 16 days ago

Best Dividend Kings: December 2025

ABBV ABM ABT ADM ADP AWR BDX

Johnson & Johnson halts mid-stage trial of experimental eczema drug

Dec 26, 2025, 8:13 AM EST - 18 days ago

Johnson & Johnson halts mid-stage trial of experimental eczema drug

J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' ruling

Dec 23, 2025, 11:41 AM EST - 21 days ago

J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' ruling

J&J vows appeal after US jury hits it with record $1.5 billion talc cancer award

Dec 23, 2025, 12:34 AM EST - 21 days ago

J&J vows appeal after US jury hits it with record $1.5 billion talc cancer award

Over $1.5 Billion Baltimore Verdict Holds Johnson & Johnson Liable Over Iconic Baby Powder

Dec 22, 2025, 11:15 PM EST - 21 days ago

Over $1.5 Billion Baltimore Verdict Holds Johnson & Johnson Liable Over Iconic Baby Powder

Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder

Dec 20, 2025, 3:55 AM EST - 24 days ago

Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder

Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson

Dec 19, 2025, 5:54 PM EST - 24 days ago

Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson

Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

Dec 18, 2025, 8:00 AM EST - 26 days ago

Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization

Dec 18, 2025, 2:09 AM EST - 26 days ago

Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization

U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)

Dec 17, 2025, 6:49 PM EST - 26 days ago

U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)

Final Trade: JNJ, NVO, UBER, BMY

Dec 15, 2025, 6:22 PM EST - 4 weeks ago

Final Trade: JNJ, NVO, UBER, BMY

BMY NVO UBER

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

Dec 15, 2025, 4:27 PM EST - 4 weeks ago

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

US FDA grants priority voucher to J&J's blood cancer treatment

Dec 15, 2025, 10:39 AM EST - 4 weeks ago

US FDA grants priority voucher to J&J's blood cancer treatment

California Jury Awards $40 Million in Landmark Talc Verdict Against Johnson & Johnson

Dec 14, 2025, 9:00 AM EST - 4 weeks ago

California Jury Awards $40 Million in Landmark Talc Verdict Against Johnson & Johnson

Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial

Dec 12, 2025, 9:08 PM EST - 4 weeks ago

Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial

U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

Dec 12, 2025, 8:25 PM EST - 4 weeks ago

U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

Johnson & Johnson: Reliable Cash Flows, Moderate Expectations

Dec 11, 2025, 7:05 PM EST - 4 weeks ago

Johnson & Johnson: Reliable Cash Flows, Moderate Expectations

GS Equity Income Fund: Q3 2025 Witnesses Fundamental Strength And Expansive Margin Opportunities

Dec 9, 2025, 9:50 PM EST - 4 weeks ago

GS Equity Income Fund: Q3 2025 Witnesses Fundamental Strength And Expansive Margin Opportunities

ACN DHI HON KVUE ORCL SSB WFC

5 defensive stocks traders are buying before the Fed rate-cut decision

Dec 9, 2025, 12:18 PM EST - 5 weeks ago

5 defensive stocks traders are buying before the Fed rate-cut decision

DUK KO NEE PG

Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma

Dec 9, 2025, 7:44 AM EST - 5 weeks ago

Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma

Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 8, 2025, 4:25 PM EST - 5 weeks ago

Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

Dec 6, 2025, 9:30 AM EST - 5 weeks ago

Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

Dec 5, 2025, 4:20 PM EST - 5 weeks ago

Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 2:13 PM EST - 5 weeks ago

Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

American Century Value Fund Q3 2025 Contributors/Detractors And Notable Trades

Dec 1, 2025, 1:36 PM EST - 6 weeks ago

American Century Value Fund Q3 2025 Contributors/Detractors And Notable Trades

BWA CNC CRM KVUE LMT NVT TER

16 Quality Stocks to Own for a Volatile Market

Dec 1, 2025, 1:23 PM EST - 6 weeks ago

16 Quality Stocks to Own for a Volatile Market

CSCO LLY XOM

SmartMoneyTradez
SmartMoneyTradez Jan. 13 at 6:02 PM
$GFS 40 > 45 > 50 $JNJ bullish
0 · Reply
ROCKSTAR_X
ROCKSTAR_X Jan. 13 at 5:19 PM
$JNJ 215 eod. possible?
0 · Reply
JohnTrack
JohnTrack Jan. 13 at 4:42 PM
$JNJ new data at 2026 American College of Neuropsychopharmacology Annual Meeting https://www.rapidticker.com/news/jnj-johnson-johnson-elevates-leadership-in-5b48d7
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 13 at 4:06 PM
$JNJ Current Stock Price: $213.13 Contracts to trade: $210 JNJ Jan 16 2026 Call Entry: $3.60 Exit: $4.77 ROI: 32% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SparkyReturns
SparkyReturns Jan. 13 at 2:55 PM
$ICU Something's up.. us. Biggest sleeper in biotech right now. GL longs. $JNJ $AMGN $MRK $MCK
0 · Reply
ConradW_
ConradW_ Jan. 13 at 2:26 PM
$JNJ Dec +7% MoM revenue lines up clean with the actual dollars: $8.01M minus $7.51M equals +$0.50M. Clean math, clean signal, no hand-waving 🔥
0 · Reply
DragonAlgo
DragonAlgo Jan. 13 at 2:21 PM
🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-01-16 | Strike: $210.00 | Type: CALL Option Plan (premium): Entry: $2.05 Stop: $1.48 TP1: $2.67 TP2: $3.48 TP3: $4.92 🔗 https://dragonalgo.com
0 · Reply
DarioQ
DarioQ Jan. 13 at 2:02 PM
$JNJ defensive anchor, if it keeps grinding higher that’s risk-off comfort without killing upside
0 · Reply
Quantumup
Quantumup Jan. 13 at 1:57 PM
BTIG reiterated $LQDA Buy/$49 $UTHR $JNJ $MRK $INSM Here's what BTIG said: https://x.com/Quantumup1/status/2011073992057139619?s=20
0 · Reply
unton
unton Jan. 13 at 1:43 PM
$PFE $MRNA $AZN $JNJ $DCOY one single pill for all types of COVID.”
0 · Reply
ZacksResearch
ZacksResearch Jan. 13 at 1:07 PM
What’s really driving $JNJ’s MedTech momentum into Q4? 👀 Cardiovascular strength and new product launches are giving the MedTech unit real traction, even as pressure in China is expected to linger into the next quarter — a mixed but telling setup ahead of the Q4 release. Get the full breakdown here 👉 https://www.zacks.com/stock/news/2816232/whats-powering-jjs-medtech-growth-ahead-of-q4-release?cid=sm-stocktwits-2-2816232-teaser-28541&ADID=SYND_STOCKTWITS_TWEET_2_2816232_TEASER_28541
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 13 at 1:03 PM
Enter: $JNJ Calls Strike Price: $210 Expiry Date: FEB 06 2026 Buy in Price: $2.87 - $3.05 Sell Price: $6.54 Profit : +128% (Turn every $1 into $2.28) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Suite510
Suite510 Jan. 13 at 12:52 PM
$JNJ $KVUE Get the popcorn 🍿 ready 😂👋🙈 Massive J&J verdicts set stage for 2026 talc litigants Company reels from Baltimore jury's $1.5B award Pat Murphy // January 12, 2026 // 7 Minute Read
0 · Reply
trading_momentum_x
trading_momentum_x Jan. 13 at 12:22 PM
$JNJ is still in an overall uptrend, but it’s near a short-term ceiling. If price holds above the recent pullback areas around the high-$190S to low-$200S, the trend remains healthy and higher prices are possible over time. If it falls back below those levels, it would suggest the stock needs more time to cool off before moving higher again.
0 · Reply
ZacksResearch
ZacksResearch Jan. 13 at 12:07 PM
$JNJ making waves in MedTech! 🚀 Despite China headwinds, J&J's MedTech sales have improved, thanks to strategic acquisitions in cardiovascular markets. Expect continued momentum in Q4, with updates on the Orthopaedics spin-off and 2026 outlook on the horizon. Discover the full potential here 👉 https://www.zacks.com/stock/news/2816232/whats-powering-jjs-medtech-growth-ahead-of-q4-release?cid=sm-stocktwits-2-2816232-body-28540&ADID=SYND_STOCKTWITS_TWEET_2_2816232_BODY_28540
0 · Reply
kyra_liu1
kyra_liu1 Jan. 13 at 12:03 PM
$JNJ is still in an overall uptrend, but it’s near a short-term ceiling. If the price holds above the recent pullback areas around the high-$190S to low-$200S, the trend remains healthy and higher prices are possible over time. If it falls back below those levels, it would suggest the stock needs more time to cool off before moving higher again.
0 · Reply
TheStockTraderHub
TheStockTraderHub Jan. 13 at 4:08 AM
$JNJ with a nice breakout move today closing above it's resistance, $212 next upside resistance with new all time highs possible target above it to $215+ Support: $208/$206.5
0 · Reply
howardlindzon
howardlindzon Jan. 13 at 2:33 AM
$DIA $IHE $JNJ $XLV
0 · Reply
BruniCharting
BruniCharting Jan. 13 at 2:09 AM
Can't ask for a cleaner chart than Johnson & Johnson ($JNJ) as large-cap healthcare continues to work well. Trendline and 50-day moving average acting as support for now. If it ain't broke, don't fix it. New highs on deck. $XLV $DIA $IHE
0 · Reply
TalkMarkets
TalkMarkets Jan. 13 at 12:51 AM
Analyzing #JeremyGrantham's Bearish Stance On U.S. Stocks - Quality #ETFs $QUAL $LRCX $GE $JNJ $LLY https://talkmarkets.com/content/us-markets/analyzing-jeremy-granthams-bearish-stance-on-us-stocks-quality-etfs?post=549689
0 · Reply
Deeznutsswapmeet
Deeznutsswapmeet Jan. 12 at 11:19 PM
$JNJ $KVUE I’m American you third world reject. Stop asking ChatGPT for market analysis. It has as much knowledge of the legal system as your dumb ass. Stop posting garbage on stocks in which you don’t own a position. Your life will be much better when you’re not watching other people make money on positions that are the exact opposite of your “predictions.”
0 · Reply
QuantTheta
QuantTheta Jan. 12 at 8:44 PM
$JNJ bouncing off support - bullish
0 · Reply